FGH10019 is a novel sterol regulatory element-binding protein ( SREBP ) inhibitor with IC 50 of 1 μM. In Vitro Treatment of the CHO-K1 cells with analog FGH10019 decreases the percentage of the mature form of SREBP-2 (68 kDa) at lower concentrations than treatment with fatostatin. Densitometric analysis of the gels indicates that the IC 50 of analog FGH10019 is approximately 1 μM, which is 5-10 times lower than the IC 50 of fatostatin (appr 10 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo FGH10019-treated chow is fed at a dose rate calculated to provide about 0.7 mg analog FGH10019 per day, at about 23 mg/kg body weight, to 5-wk-old male ob/ob mice weighing an average of appr 30 g. After 8 wk on the analog 24-treated chow, the mice gain 8-9 % less weight than control mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:IC50: 1 μM (SREBP)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
FGH10019
CAS number：1046045-61-7(DMSO) molecular formula：C18H19N3O2S2
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1046045-61-7(DMSO) | molecular formula | C18H19N3O2S2 |
| molecular weight | 373.49 g/mol | Exact mass | 10mM in DMSO |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
